MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2026.1823718

Медицинская библиотека · Frontiers in endocrinology · 2026

Clinical predictors of tocilizumab response in moderate-to-severe thyroid eye disease: a large single-center retrospective cohort study.

Lu Ming, Wang Luqiang, Wang Ziqi, Song Zhihui

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Tocilizumab (TCZ), an interleukin-6 receptor antagonist, is recommended as a second-line therapy for thyroid eye disease (TED), yet the clinical determinants of treatment response remain poorly defined. Identifying reliable predictors of response is essential for patient selection and precision use.

METHODS

We conducted a single-center retrospective cohort study of 234 patients with moderate-to-severe TED treated with intravenous TCZ (8 mg/kg every 4 weeks) at Beijing Tongren Hospital from January 2023 to December 2025. Treatment response was defined as a reduction in Clinical Activity Score (CAS) of ≥2 points from baseline. Candidate predictors were entered into a multivariate binary logistic regression. ROC analysis identified optimal cut-off values.

RESULTS

Following TCZ treatment, CAS decreased significantly from 3.42 ± 0.61 to 1.70 ± 0.67 (P < 0.001), and TRAb declined from 10.35 ± 11.99 IU/L to 4.46 ± 6.73 IU/L (P < 0.001). Of 234 patients with complete paired data, 155 (66.2%) were Responders. Responders had higher TRAb (12.17 vs. 7.07 IU/L), fibrinogen (FIB; 2.83 vs. 2.58 g/L), and HDL-cholesterol (HDL-C; 1.37 vs. 1.24 mmol/L), and shorter disease duration (7.91 vs. 10.08 months; all P < 0.05). Multivariate analysis identified four independent predictors: shorter disease duration (OR = 0.962 per month, 95% CI 0.928-0.998, P = 0.038), higher TRAb (OR = 1.036 per IU/L, 95% CI 1.004-1.068, P = 0.025), higher FIB (OR = 1.869 per g/L, 95% CI 1.097-3.184, P = 0.021), and higher HDL-C (OR = 2.665 per mmol/L, 95% CI 1.175-6.041, P = 0.019). The composite model achieved AUC = 0.695 (95% CI 0.625-0.765, P < 0.001).

CONCLUSIONS

TCZ produces clinically meaningful and multi-dimensionally validated response with moderate-to-severe TED. Shorter disease duration, higher baseline TRAb, FIB, and HDL-C independently predict response, offering a preliminary framework to inform patient selection. These findings provide the largest real-world evidence to date for guiding precision use of TCZ in TED.

Для цитирования: Lu Ming, Wang Luqiang, Wang Ziqi, Song Zhihui. Clinical predictors of tocilizumab response in moderate-to-severe thyroid eye disease: a large single-center retrospective cohort study.. Frontiers in endocrinology. 2026. DOI: 10.3389/fendo.2026.1823718.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.